UP-CAPTAIn: Using Probability of Community-Acquired Pneumonia to Tailor Antimicrobials Among Inpatients

Sponsor
Jonathan Baghdadi (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT05976581
Collaborator
Centers for Disease Control and Prevention (U.S. Fed)
1,500
2
14.5

Study Details

Study Description

Brief Summary

The goal of this prospective randomized study is to improve antibiotic use among hospitalized patients with suspected pneumonia. An alert was built into the electronic health record to guide use of diagnostic testing based on probability of bacterial pneumonia. Patients with test results suggesting viral infection will be randomized to either: (1) receive a structured communication from the antimicrobial stewardship team to de-escalate antibiotics or (2) usual care.

Condition or Disease Intervention/Treatment Phase
  • Behavioral: Electronic alert
  • Behavioral: Structured communication of test results
N/A

Detailed Description

Low-risk patients with viral pneumonia do not benefit from and may be harmed by antibiotic therapy. In this study, an alert will appear in the electronic health record of patients undergoing molecular diagnostic testing for respiratory symptoms that provides options for diagnostic testing based on pre-test probability of bacterial infection. Patients with test results suggesting possible viral infection will be randomized to either usual care or to receive test results along with structured guidance from antimicrobial stewardship to consider discontinuing or de-escalating antibiotics. This guidance, which will include an explicit calculation of the post-test probability of bacterial infection based on considering risk factors, vital signs, symptoms, and available imaging, will be communicated to the primary care team via direct electronic message and a summary note in the patient's chart. The final decision on whether to continue antibiotic therapy will be up to the primary team. The primary outcome of interest will be in-hospital antibiotic use. Safety outcomes will include length of stay, readmissions, hospital-free days, and mortality.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
1500 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
None (Open Label)
Primary Purpose:
Diagnostic
Official Title:
Using Probability of Community-Acquired Pneumonia to Tailor Antimicrobials Among Inpatients
Anticipated Study Start Date :
Aug 1, 2023
Anticipated Primary Completion Date :
Aug 15, 2024
Anticipated Study Completion Date :
Oct 15, 2024

Arms and Interventions

Arm Intervention/Treatment
Experimental: Electronic alert plus structured communication of test results

An electronic health record alert will guide diagnostic testing for pneumonia. For patients with low or moderate probability of bacterial pneumonia, test results will be communicated to the primary team with guidance to consider discontinuing or de-escalating antibiotics.

Behavioral: Electronic alert
An alert will appear in the electronic health record that provides options for diagnostic testing based on low, medium, or high probability of bacterial pneumonia.

Behavioral: Structured communication of test results
A clinical research team member will send an electronic message to the primary care team on behalf of the antimicrobial stewardship program with structured guidance to stop or de-escalate antibiotics and document these recommendations in the patient's chart.

Active Comparator: Electronic alert without structured communication of test results

An electronic health record alert will guide diagnostic testing for pneumonia. The primary care team will access and interpret test results and decide upon composition and duration of antimicrobial without external guidance.

Behavioral: Electronic alert
An alert will appear in the electronic health record that provides options for diagnostic testing based on low, medium, or high probability of bacterial pneumonia.

Outcome Measures

Primary Outcome Measures

  1. Hospital antibiotic days of therapy [Up to 90 days after randomization]

    The aggregate sum of days for which any amount of a specific antimicrobial agent was administered during the hospital encounter, from arrival in the emergency department or on the hospital ward until discharge.

Secondary Outcome Measures

  1. Hospital length of stay [Up to 90 days after randomization]

    Duration of hospitalization from admission to discharge

  2. In-hospital mortality [Up to 90 days after randomization]

    Death or discharge to hospice during initial hospitalization for any cause

  3. Readmissions within 30-days of randomization [Within 30 days after randomization]

    Readmissions for any cause within 30-days of randomization

  4. C. difficile infections in the 30-days post-randomization [Within 30 days after randomization]

    Positive test for C. difficile associated with initiation of antibiotics targeting C. difficile.

  5. Acute kidney injury [Within 14 days of randomization]

    Defined by an elevation in creatinine of > 0.5mg/dl or 2x baseline in a patient without previous end-stage renal disease.

  6. Ventilator-free days in the 30-days post-randomization [30 days after randomization.]

    Days without a requirement for mechanical ventilation in the 30 days after randomization.

  7. Hospital-free days in the 30-days post-randomization [30 days after randomization.]

    Days without hospitalization in the 30 days after randomization.

  8. Antibiotic de-escalations within 72 hours after initiation [3 days after randomization.]

    Including narrowing, discontinuing, or converting the route of administration from intravenous to oral.

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Adult patients admitted to the University of Maryland Medical Center or University of Maryland Medical Center-Midtown Campus who are prescribed antibiotics for suspected community-acquired respiratory infection.

  • Protocol-based diagnostic testing supports possible viral infection, either by positive molecular test or low procalcitonin value.

Exclusion Criteria:
  • Hospitalization for >72 hours prior to protocol-based diagnostic testing.

  • Previous molecular testing for viral infection during the same hospital encounter.

  • Severely immunosuppressed, defined as having hematologic malignancy, solid organ tumor on chemotherapy, or solid organ transplant on immunosuppression

Contacts and Locations

Locations

No locations specified.

Sponsors and Collaborators

  • Jonathan Baghdadi
  • Centers for Disease Control and Prevention

Investigators

  • Principal Investigator: Daniel J. Morgan, MD, MS, University of Maryland, Baltimore

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Jonathan Baghdadi, Assistant Professor, University of Maryland, Baltimore
ClinicalTrials.gov Identifier:
NCT05976581
Other Study ID Numbers:
  • 2023p00103497
First Posted:
Aug 4, 2023
Last Update Posted:
Aug 4, 2023
Last Verified:
Jul 1, 2023
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Jonathan Baghdadi, Assistant Professor, University of Maryland, Baltimore
Additional relevant MeSH terms:

Study Results

No Results Posted as of Aug 4, 2023